Navigation Links
New Agreements Underscore QIAGEN's Leadership in Bioinformatics
Date:2/2/2016

HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ --

FDA centers and researchers gain access to QIAGEN's enhanced solutions for applications including microbial and microbiome analysis

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications.

QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing.

Click here for full press release

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
http://www.twitter.com/qiagen
https://www.facebook.com/QIAGEN
pr.qiagen.com

Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com


'/>"/>
SOURCE QIAGEN NV
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. QIAGEN Reaches Milestone With Portfolio of Master Collaboration Agreements for Pharma Companion Diagnostics
2. Agreements & Partnerships, a Key Strategy Adopted by Leading Market Players to Foster their Growth in the Global Oncology Information System Market - MarketsandMarkets
3. Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
4. Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
5. Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech, and Diagnostics
6. A Revelation on Asset Purchase Terms and Agreements in Pharma, Biotech, and Diagnostics
7. Molecular Diagnostics Partnering Terms and Agreements : Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz
8. Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us
9. Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
10. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
11. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... The Blavatnik Family Foundation and the ... of the 2017 Blavatnik Regional Awards for Young Scientists. Established in 2007, ... the New York Academy of Sciences to honor the excellence of outstanding postdoctoral ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):